McKesson Corporation has posted a 6.4% weekly gain to $784.23, yet the most striking feature of this week's setup is a sudden and sharp rebuild in short interest — even as options traders move in the opposite direction, pricing in less downside than at any point in recent months.
The short-interest move deserves attention. Measured as a share of free float, short interest has more than doubled in the past month — rising from roughly 2% in early May to 4.1% now. The single-day jump on June 9 was particularly abrupt: estimated shares short rose nearly 37% in one session, adding over 1.3 million shares. That one-month build of 142% is a meaningful rate of change even if the absolute level — at 4.1% of float — isn't extreme territory for a healthcare distributor. The borrow market, however, is nowhere near stressed: availability remains very loose at roughly 3,680%, meaning there are vastly more shares available to lend than are currently borrowed. Borrowing costs have crept up about 12% on the week but remain low in absolute terms at 0.48%. This is a short interest build driven by conviction rather than forced by a tight lending market.
Options positioning tells a contradictory story, and the contrast matters. The put/call ratio has drifted to 0.56 — nearly 1.5 standard deviations below its 20-day average of 0.59 — and is approaching the 52-week low of 0.50. That means options traders are more call-heavy than usual, reflecting a bias toward upside participation rather than downside hedging. The divergence between a rapidly building short book and a PCR near annual lows captures the genuine tension in this setup: short sellers are adding exposure into a rally, while options flow suggests the broader options market is not endorsing the bearish thesis.
The Street is largely constructive but has spent much of May trimming targets. Barclays cut its price objective from $1,050 to $925 today while maintaining Overweight, the most recent in a string of reductions that also included JPMorgan lowering to $1,015 from $1,107 and Wells Fargo trimming to $812. UBS bucked the trend post-earnings, raising to $1,050 from $1,000 and holding its Buy. The consensus mean target of $941 implies about 20% upside from current levels — a meaningful gap, though that figure has compressed as targets have been walked down. Factor scores support the buy-side case on a few dimensions: the analyst recommendation differential ranks in the 92nd percentile, EPS surprise in the 77th, and 90-day EPS momentum in the 82nd. Forward earnings growth, however, is a notable weak spot, ranking in just the 17th percentile. The trailing PE of 16.7x has expanded roughly 1.1 turns over the past 30 days, tracking the stock's recovery. The next quarterly print arrives August 5.
Insider activity is uniformly in one direction: sell. The Chief Legal Officer liquidated $2.7 million of stock on May 26. The Chief Strategy Officer has sold on four separate occasions in the past three weeks. The HR Director sold $1.3 million in early June. All trades carry low significance scores — most appear to be programmatic disposals rather than discretionary exits — but the 90-day net value of sales exceeds $10 million. No offsetting purchases have appeared in the data. That isn't unusual at this price level for large-cap healthcare, but the clustering is worth noting alongside the short-interest build.
The most comparable highly-correlated peer, CAH, has run even harder — up 9.1% on the week versus MCK's 6.4% — and COR added 5.6%. The sector move is broad. What to watch into August is whether the short rebuild sustains at these levels or begins to unwind as the stock approaches the cluster of analyst targets in the $920–$950 range, and whether the options market — currently pricing call-heavy positioning — starts to shift back toward the defensive skew that dominated through April and early May.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
